Loading clinical trials...
Loading clinical trials...
Phase II Multicenter Randomized Trial to Assess the Efficacy and Safety of First Line Nivolumab in Combination With Paclitaxel in Subjects With R/M HNSCC Unable for Cisplatin-based Chemotherapy (NIVOTAX)
Conditions
Interventions
Nivolumab + Paclitaxel
Cetuximab + Paclitaxel
Locations
21
Spain
Hospital Universitario Marqués de Valdecilla
Santander, Cantabria, Spain
Hospital Universitario Donostia- Donostia Unibertsitate Ospitalea
San Sebastián, San Sebastían, Spain
Centro Oncoloxico de Galicia
A Coruña, Spain
Hospital Universitari Germans Trias i Pujol de Badalona
Badalona, Spain
Hospital Universitari Vall d'Hebron
Barcelona, Spain
Hospital Clínic de Barcelona
Barcelona, Spain
Start Date
June 3, 2020
Primary Completion Date
September 1, 2023
Completion Date
March 21, 2024
Last Updated
June 26, 2025
NCT07090317
NCT07408063
Lead Sponsor
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions